Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and a burning sensation in the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressants.

The Bullous Pemphigoid pipeline drugs market research report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects.

Bullous Pemphigoid Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4, C-C Chemokine Receptor Type 3, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C1s Subcomponent, Complement C5, Eotaxin, Granzyme B, and Heat Shock Protein 90 among others. Phosphodiesterase 4 leads this segment of the Bullous Pemphigoid pipeline drugs market.

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Targets

Bullous Pemphigoid Pipeline Drugs Market Analysis, by TargetsFor more Bullous Pemphigoid pipeline drugs market target insights, download a free report sample

Bullous Pemphigoid Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Bullous Pemphigoid pipeline drugs market are Phosphodiesterase 4 Inhibitor, C-C Chemokine Receptor Type 3 Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C1s Subcomponent Inhibitor, Complement C5 Inhibitor, and among others. Phosphodiesterase 4 Inhibitor leads the Bullous Pemphigoid pipeline drugs market in terms of MoA.

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Mechanisms of Action

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample

Bullous Pemphigoid Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Bullous Pemphigoid pipeline drugs market are intravenous, subcutaneous, oral, and topical. Intravenous leads the Bullous Pemphigoid pipeline drugs market in terms of RoA.

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Routes of Administration

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample

Bullous Pemphigoid Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Bullous Pemphigoid pipeline drugs market are small molecule, monoclonal antibody, fusion protein, protein, and recombinant protein. Small Molecule leads the Bullous Pemphigoid pipeline drugs market in terms of molecule types.

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Molecule Types

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the Bullous Pemphigoid pipeline drugs market, download a free report sample

Bullous Pemphigoid Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Bullous Pemphigoid pipeline drugs market are Immungenetics AG, Akari Therapeutics Plc, Alkahest Inc, Alpine Immune Sciences Inc, Amgen Inc, Argenx SE, ARTham Therapeutics Inc, Innate Pharma SA, Kyowa Kirin Co Ltd, Regeneron Pharmaceuticals Inc, Regranion LLC, Sanofi, Satellos Bioscience Inc, SFA Therapeutics Inc, and viDA Therapeutics Inc among others. Immungenetics AG has the highest number of products under development.

Bullous Pemphigoid Pipeline Drugs Market Analysis, by Companies

Bullous Pemphigoid Pipeline Drugs Market Analysis, by CompaniesTo know more about the Bullous Pemphigoid pipeline drugs companies, download a free report sample

Bullous Pemphigoid Pipeline Drugs Market Report Overview

Key Targets Phosphodiesterase 4, C-C Chemokine Receptor Type 3, C5a Anaphylatoxin Chemotactic Receptor 1, Complement C1s Subcomponent, Complement C5, Eotaxin, Granzyme B, and Heat Shock Protein 90 among others
Key Mechanisms of Action Phosphodiesterase 4 Inhibitor, C-C Chemokine Receptor Type 3 Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Complement C1s Subcomponent Inhibitor, Complement C5 Inhibitor, and among others
Key Routes of Administration Intravenous, Subcutaneous, Oral, and Topical
Key Molecule Types Small Molecule, Monoclonal Antibody, Fusion Protein, Protein, and Recombinant Protein
Key Companies Immungenetics AG, Akari Therapeutics Plc, Alkahest Inc, Alpine Immune Sciences Inc, Amgen Inc, Argenx SE, ARTham Therapeutics Inc, Innate Pharma SA, Kyowa Kirin Co Ltd, Regeneron Pharmaceuticals Inc, Regranion LLC, Sanofi, Satellos Bioscience Inc, SFA Therapeutics Inc, and viDA Therapeutics Inc among others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid.
  • The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bullous Pemphigoid therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bullous Pemphigoid therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Bullous Pemphigoid

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Bullous Pemphigoid pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Akari Therapeutics Plc
Alkahest Inc
Alpine Immune Sciences Inc
Amgen Inc
Argenx SE
ARTham Therapeutics Inc
Immungenetics AG
Innate Pharma SA
Kyowa Kirin Co Ltd
Regeneron Pharmaceuticals Inc
Regranion LLC
Sanofi
Satellos Bioscience Inc
SFA Therapeutics Inc
viDA Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bullous Pemphigoid – Overview

Bullous Pemphigoid – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bullous Pemphigoid – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bullous Pemphigoid – Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Alkahest Inc

Alpine Immune Sciences Inc

Amgen Inc

Argenx SE

ARTham Therapeutics Inc

Immungenetics AG

Innate Pharma SA

Kyowa Kirin Co Ltd

Regeneron Pharmaceuticals Inc

Regranion LLC

Sanofi

Satellos Bioscience Inc

SFA Therapeutics Inc

viDA Therapeutics Inc

Bullous Pemphigoid – Drug Profiles

ALPN-303 – Drug Profile

Product Description

Mechanism Of Action

apremilast – Drug Profile

Product Description

Mechanism Of Action

ART-648 – Drug Profile

Product Description

Mechanism Of Action

avdoralimab – Drug Profile

Product Description

Mechanism Of Action

benralizumab – Drug Profile

Product Description

Mechanism Of Action

bertilimumab – Drug Profile

Product Description

Mechanism Of Action

dimethyl fumarate – Drug Profile

Product Description

Mechanism Of Action

dupilumab – Drug Profile

Product Description

Mechanism Of Action

efgartigimod alfa – Drug Profile

Product Description

Mechanism Of Action

lazucirnon hydrochloride – Drug Profile

Product Description

Mechanism Of Action

RGRN-305 – Drug Profile

Product Description

Mechanism Of Action

SFA-003 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders – Drug Profile

Product Description

Mechanism Of Action

sutimlimab – Drug Profile

Product Description

Mechanism Of Action

Synthetic Coversin – Drug Profile

Product Description

Mechanism Of Action

VTI-1002 – Drug Profile

Product Description

Mechanism Of Action

Bullous Pemphigoid – Dormant Projects

Bullous Pemphigoid – Discontinued Products

Bullous Pemphigoid – Product Development Milestones

Featured News & Press Releases

Jan 15, 2021: ARTham Therapeutics presents phase I results for ART-648 at ASCPT 2021 Annual Meeting

Mar 30, 2020: ART-648 program was selected as a drug discovery project for orphan diseases to be supported by AMED

Jan 20, 2020: AstraZeneca studies Fasenra in three new trials for skin diseases

Sep 11, 2018: Bertilimumab granted Fast Track Designation for the treatment of Bullous Pemphigoid

Aug 20, 2018: Bertilimumab granted Orphan Drug Designation for the treatment of Bullous Pemphigoid

Jul 30, 2018: Immune Pharmaceuticals receives positive opinion for orphan drug designation in the European Union for Bertilimumab for the treatment of bullous pemphigoid

May 15, 2018: Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Mar 12, 2018: Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

Sep 27, 2017: Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Aug 28, 2017: Immune Pharmaceuticals Provides update on bertilimumab

Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid

Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid

Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid

Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Bullous Pemphigoid, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Bullous Pemphigoid – Pipeline by Akari Therapeutics Plc, 2022

Bullous Pemphigoid – Pipeline by Alkahest Inc, 2022

Bullous Pemphigoid – Pipeline by Alpine Immune Sciences Inc, 2022

Bullous Pemphigoid – Pipeline by Amgen Inc, 2022

Bullous Pemphigoid – Pipeline by Argenx SE, 2022

Bullous Pemphigoid – Pipeline by ARTham Therapeutics Inc, 2022

Bullous Pemphigoid – Pipeline by Immungenetics AG, 2022

Bullous Pemphigoid – Pipeline by Innate Pharma SA, 2022

Bullous Pemphigoid – Pipeline by Kyowa Kirin Co Ltd, 2022

Bullous Pemphigoid – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Bullous Pemphigoid – Pipeline by Regranion LLC, 2022

Bullous Pemphigoid – Pipeline by Sanofi, 2022

Bullous Pemphigoid – Pipeline by Satellos Bioscience Inc, 2022

Bullous Pemphigoid – Pipeline by SFA Therapeutics Inc, 2022

Bullous Pemphigoid – Pipeline by viDA Therapeutics Inc, 2022

Bullous Pemphigoid – Dormant Projects, 2022

Bullous Pemphigoid – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Bullous Pemphigoid, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.